Fred Fiedorek
Direttore Tecnico/Scientifico/R&S presso VERVE THERAPEUTICS, INC.
Posizioni attive di Fred Fiedorek
Società | Posizione | Inizio | Fine |
---|---|---|---|
VERVE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 18/09/2023 | - |
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Direttore Tecnico/Scientifico/R&S | - | - |
Storia della carriera di Fred Fiedorek
Precedenti posizioni note di Fred Fiedorek
Società | Posizione | Inizio | Fine |
---|---|---|---|
RHYTHM PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 11/12/2014 | 15/10/2018 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Direttore Tecnico/Scientifico/R&S | - | - |
Foresite Capital Management LLC
Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Consulente / Consigliere | 01/12/2020 | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Formazione di Fred Fiedorek
Harvard Medical School | Doctorate Degree |
Yale University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
RHYTHM PHARMACEUTICALS, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
VERVE THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Foresite Capital Management LLC
Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Finance |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Fred Fiedorek
- Esperienza